EDAP TMS (EDAP) has released an update.
EDAP TMS S.A., a company specializing in robotic High-Intensity Focused Ultrasound (HIFU) technologies for prostate cancer, reported significant growth in 2023 with record revenues, increased adoption of its Focal One systems, and significant clinical and regulatory milestones. Notably, the company received a positive opinion from the French National Authority for Health and reimbursement approval in Switzerland for HIFU prostate cancer treatments. Looking ahead, EDAP anticipates a strong pipeline for Focal One, despite a modest elongation in purchasing cycles due to economic conditions, and appeals to shareholders to support upcoming resolutions in their General Meeting.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.
